Kraj: Kanada
Język: angielski
Źródło: Health Canada
TELMISARTAN (TELMISARTAN SODIUM); HYDROCHLOROTHIAZIDE
TEVA CANADA LIMITED
C09DA07
TELMISARTAN AND DIURETICS
80MG; 12.5MG
TABLET
TELMISARTAN (TELMISARTAN SODIUM) 80MG; HYDROCHLOROTHIAZIDE 12.5MG
ORAL
30/100/500
Prescription
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0244783001; AHFS:
APPROVED
2012-02-06
_ _ TEVA-TELMISARTAN HCTZ _ _ Page 1 of 72 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TEVA-TELMISARTAN HCTZ Telmisartan and Hydrochlorothiazide Tablets Tablet, 80 mg Telmisartan (as Telmisartan Sodium) / 12.5 mg Hydrochlorothiazide, Oral Tablet, 80 mg Telmisartan (as Telmisartan Sodium) / 25 mg Hydrochlorothiazide, Oral Teva standard Angiotensin II AT 1 Receptor Blocker / Diuretic Teva Canada Limited 30 Novopharm Court Toronto, ON M1B 2K9 Canada www.tevacanada.com Date of Initial Authorization: February 6, 2012 Date of Revision: February 24, 2023 Submission Control Number: 267285 _ _ TEVA-TELMISARTAN HCTZ _ _ Page 2 of 72 RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 10/2021 7 WARNINGS AND PRECAUTIONS 02/2023 4 DOSAGE AND ADMINISTRATION 02/2023 7 WARNINGS AND PRECAUTIONS 02/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES .............................................................................................. 2 TABLE OF CONTENTS ................................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION..................................................................... 4 1 INDICATIONS .................................................................................................................... 4 1.1 Pediatrics .................................................................................................................... 4 1.2 Geriatrics .................................................................................................................... 4 2 CONTRAINDICATIONS ....................................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX .................................................................. 5 4 DOSAGE AND ADMINISTRATION....................................................................................... 5 4.1 Dos Przeczytaj cały dokument